North America Brain Implants Market Forecast to 2030 - Regional Analysis - by Treatment, Application, and End User (Hospitals and Specialized Clinics/Neurological Centers)

List of Tables

The North America brain implants market was valued at US$ 3,131.97 million in 2022 and is expected to reach US$ 7,768.72 million by 2030; it is estimated to grow at a CAGR of 12.0% from 2022 to 2030.

Surging Prevalence of Neurological Disorders with Increasing Geriatric Population Fuels North America Brain Implants Market

With age, elderly people are likely to develop neurological disorders that impact their mobility. Alzheimer's disease, epilepsy, Parkinson's disease (PD), and dystonia are among the most common neurological disorders affecting the geriatric population. According to the 2020 population statistics by the US Census Bureau, the geriatric population reached 55.8 million, i.e., 16.8% of the national population; nearly 1 in 6 people in the country were aged 65 and above in 2020. Further, as per the data published by the Fraser Institute, the share of Canada's population aged 65 or older increased from 14% in 2010 to 19% in 2022 and is expected to reach 22.5% by 2030. According to an article published by UpToDate Inc. in August 2021, the incidence rate of epilepsy rises with age and is highest among patients aged 75 and above.

Countries such as the US and Canada have high prevalence rates of movement disorders and psychiatric disorders associated with growing geriatric populations. According to the Parkinson's Foundation, Parkinson's symptoms are common at an average age of 60. For instance, ~90,000 Americans are diagnosed with PD yearly. The organization also states that the incidence of PD increases with age; nearly 1 million people in the US are living with PD, and the number is expected to reach 1.2 million by 2030. According to an article titled "Alzheimer's disease: Can deep brain stimulation help alleviate symptoms" published in April 2023, ~32 million people worldwide have Alzheimer's disease. As per the Alzheimer's Disease Research Factsheet, published by BrightFocus Foundation in October 2022, ~500,000 new cases of Alzheimer's disease were diagnosed in 2022 in the US. The incidence rate of Alzheimer's increases with age. ~6.5 million Americans aged 65 and above are suffering from Alzheimer's disease, and the number is expected to reach 12.7 million by 2050. According to the World Health Organization (WHO) stats released in February 2022, approximately 50 million people suffer from epilepsy, which is one of the most common neurological diseases worldwide.

The increasing incidence of neurological diseases, coupled with the growing geriatric population, drives the demand for brain implants to treat and manage the disease. The deep brain stimulation (DBS) technique is used to treat epilepsy cases due to the low therapeutic response exhibited by the patient's body to medication during seizures and reduced success rates associated with surgeries. Researchers from the University of North Carolina at Chapel Hill claim to have generated new neurons in the brain, which can be stimulated using DBS. DBS for Alzheimer's involves utilizing an implanted device similar to a heart pacemaker and two attached wires that deliver mild electrical pulses directly to the fornix area of the brain. Electrical stimulation can activate the memory circuitry in the brain to sharpen its function. Thus, neural implants such as DBS and vagus nerve stimulation are increasingly being used to treat patients with PD and other neurological conditions.

North America Brain Implants Market Overview

The North America brain implants market is segmented into the US, Canada, and Mexico. In 2022, the US held the largest market share in this region and is expected to continue its dominance during the forecast period. The increasing prevalence of neurological diseases such as Parkinson's disease (PD), growing awareness about neurological disorders, positive research results, and growing investments in developing various stimulators are among the main factors driving the overall market growth for brain implants in the US. According to the Parkinson's Foundation, 930,000 people in the US were suffering from PD in 2020, and the number is expected to increase to 1.2 million by 2030. Brain implants, such as deep brain stimulation (DBS), have proven to be potential treatment options for PD. DBS devices have been observed to be effective in controlling tremors associated with PD. As per the Oregon Health & Science University (OSHU) Brain Institute, in the US, ~90% of patients with essential tremors experienced moderate relief from symptoms after DBS.

According to a study titled "2022 Alzheimer's disease facts and figures," published in March 2022, ~6.5 million Americans aged 65 and above were found to have Alzheimer's disease in 2022, and the number is projected to rise to 13.8 million by 2060. Moreover, major market players focus on introducing new versions of DBS devices. In March 2023, researchers at Michigan Technological University used neuromorphic computing to improve the efficacy and energy efficiency of DBS systems used to treat PD. Similarly, researchers from the University of North Carolina at Chapel Hill discovered that they were able to generate new neurons in the brain and stimulate them using DBS. This process helped restore cognitive and noncognitive functions in a mouse model that had Alzheimer's disease.

Technological advancements and new product launches drive the growth of the US brain implants market. In January 2020, Abbott's Infinity DBS System received US Food and Drug Administration (FDA) approval for treating PD. This system targets a specific area of the brain (the inner globus pallidus), which is associated with the symptoms of PD. In September 2020, Boston Scientific announced the European launch of the WaveWriter Alpha portfolio of SCS systems. In May 2023, Abbott received approval from the US FDA for spinal cord stimulator (SCS) devices to treat chronic back pain in people who are not recommended to receive back surgery. In September 2023, Neuralink received approval from an independent review board to initiate recruitment for the first human trial of brain implants for paralysis patients. The study will involve a robot to surgically place a brain-computer interface (BCI) implant in the area of the brain that controls bodily movements.

Therefore, increasing prevalence of neurological diseases, rising research and development activities, and technological advancements in brain implants are expected to bolster the brain implants market growth in the future.

North America Brain Implants Market Revenue and Forecast to 2030 (US$ Million)

North America Brain Implants Market Segmentation

The North America brain implants market is segmented into treatment, application, end user, and country.

Based on treatment, the North America brain implants market is classified into deep brain stimulation, spinal cord stimulation, vagus nerve stimulator, invasive and non-invasive brain-computer interface, responsive neurostimulation for seizures, auditory brainstem implant, and ophthalmic aid/implant. Further, the auditory brainstem implant segment is bifurcated into retrocochlear hearing impairment and cochlear hearing impairment. The spinal cord stimulation segment held the largest share in 2022.

In terms of application, the North America brain implants market is categorized into chronic pain, Parkinson's disease, Alzheimer's disease, epilepsy, essential tremor, depression, dystonia, amyotrophic lateral sclerosis (ALS), and neurofibromatosis 2. The chronic pain segment held the largest share in 2022.

Based on end user, the North America brain implants market is bifurcated into hospitals and specialized clinics/neurological centers. The hospitals segment held the largest share in 2022.

Based on country, the North America brain implants market is segmented the US, Canada, and Mexico. The US dominated the North America brain implants market in 2022.

Abbott Laboratories, Blackrock Microsystems Inc, Boston Scientific Corp, BrainGate, Fisher Wallace Laboratories Inc, Functional Neuromodulation Ltd, Medtronic Plc, Neuralink Corp, NeuroPace Inc, NeuroSky Inc, Neurospine LLC, ONWARD Medical NV, Paradromics Inc, Renishaw Plc, and Synchron Inc are some of the leading companies operating in the North America brain implants market.

Product Code: BMIRE00029805

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America Brain Implants Market Landscape

4.1 Overview
4.2 North America PEST Analysis

5. North America Brain Implants Market - Key Industry Dynamics

5.1 Key Market Drivers
- 5.1.1 Surging Prevalence of Neurological Disorders with Increasing Geriatric Population
- 5.1.2 Rising Number of Spinal Cord Injuries
5.2 Key Market Restraints
- 5.2.1 High Cost Associated with Brain Implant Devices and Procedures
5.3 Key Market Opportunities
- 5.3.1 Strategic Initiatives by Companies
5.4 Key Future Trends
- 5.4.1 Technological Advancements such as Miniaturization, Artificial Intelligence, and Modern Brain-Machine Interfaces
5.5 Impact Analysis:

6. Brain Implants Market - North America Market Analysis

6.1 Overview
6.2 North America Brain Implants Market Revenue (US$ Mn), 2022 - 2030

7. North America Brain Implants Market - Revenue and Forecast to 2030 - by Treatment

7.1 Overview
7.2 North America Brain Implants Market Revenue Share, by Treatment, 2022 & 2030 (%)
7.3 Deep Brain Stimulation
- 7.3.1 Overview
- 7.3.2 Deep Brain Stimulation: North America Brain Implants Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Spinal Cord Stimulation
- 7.4.1 Overview
- 7.4.2 Spinal Cord Stimulation: North America Brain Implants Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Vagus Nerve Stimulator
- 7.5.1 Overview
- 7.5.2 Vagus Nerve Stimulator: North America Brain Implants Market - Revenue and Forecast to 2030 (US$ Million)
7.6 Invasive and Non-Invasive Brain-Computer Interfaces
- 7.6.1 Overview
- 7.6.2 Invasive and Non-Invasive Brain-Computer Interfaces: North America Brain Implants Market - Revenue and Forecast to 2030 (US$ Million)
7.7 Responsive Neurostimulation for Seizures
- 7.7.1 Overview
- 7.7.2 Responsive Neurostimulation for Seizures: North America Brain Implants Market - Revenue and Forecast to 2030 (US$ Million)
7.8 Auditory Brainstem Implant
- 7.8.1 Overview
- 7.8.2 Auditory Brainstem Implant: North America Brain Implants Market - Revenue and Forecast to 2030 (US$ Million)
  - 7.8.2.1 Retrocochlear Hearing Impairment
    - 7.8.2.1.1 Retrocochlear Hearing Impairment: Auditory Brainstem Implants Market- Revenue and Forecast to 2030 (US$ Million)
  - 7.8.2.2 Cochlear Hearing Impairment
    - 7.8.2.2.1 Cochlear Hearing Impairment: Auditory Brainstem Implants Market- Revenue and Forecast to 2030 (US$ Million)
7.9 Ophthalmic Aids/Implant
- 7.9.1 Overview
- 7.9.2 Ophthalmic Aids/Implant: North America Brain Implants Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Brain Implants Market - Revenue and Forecast to 2030 - by Application

8.1 Overview
8.2 North America Brain Implants Market Revenue Share, by Application 2022 & 2030 (%)
8.3 Chronic Pain
- 8.3.1 Overview
- 8.3.2 Chronic Pain: North America Brain Implants Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Parkinson's disease
- 8.4.1 Overview
- 8.4.2 Parkinson's disease: North America Brain Implants Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Alzheimer's disease
- 8.5.1 Overview
- 8.5.2 Alzheimer's disease: North America Brain Implants Market - Revenue and Forecast to 2030 (US$ Million)
8.6 Epilepsy
- 8.6.1 Overview
- 8.6.2 Epilepsy: North America Brain Implants Market - Revenue and Forecast to 2030 (US$ Million)
8.7 Essential Tremor
- 8.7.1 Overview
- 8.7.2 Essential Tremor: North America Brain Implants Market - Revenue and Forecast to 2030 (US$ Million)
8.8 Depression
- 8.8.1 Overview
- 8.8.2 Depression: North America Brain Implants Market - Revenue and Forecast to 2030 (US$ Million)
8.9 Dystonia
- 8.9.1 Overview
- 8.9.2 Dystonia: North America Brain Implants Market - Revenue and Forecast to 2030 (US$ Million)
8.10 Amyotrophic Lateral Sclerosis
- 8.10.1 Overview
- 8.10.2 Amyotrophic Lateral Sclerosis (ALS): North America Brain Implants Market - Revenue and Forecast to 2030 (US$ Million)
8.11 Neurofibromatosis 2
- 8.11.1 Overview
- 8.11.2 Neurofibromatosis 2: North America Brain Implants Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Brain Implants Market - Revenue and Forecast to 2030 - by End-User

9.1 Overview
9.2 North America Brain Implants Market Revenue Share, by End-User, 2022 & 2030 (%)
9.3 Hospitals
- 9.3.1 Overview
- 9.3.2 Hospitals: North America Brain Implants Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Specialized Clinics / Neurological Centers
- 9.4.1 Overview
- 9.4.2 Specialized Clinics / Neurological Centers: North America Brain Implants Market - Revenue and Forecast to 2030 (US$ Million)

10. North America Brain Implants Market - Geographical Analysis

10.1 North America North America Brain Implants Market, by Key Country-Revenue (2022)

11. Brain Implants Market-Industry Landscape

11.1 Overview
11.2 Growth Strategies in Brain Implants Market
11.3 Organic Growth Strategies
- 11.3.1 Overview
11.4 Inorganic Growth Strategies
- 11.4.1 Overview

12. Company Profiles

12.1 Boston Scientific Corp
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Medtronic Plc
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Functional Neuromodulation Ltd
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 SWOT Analysis
- 12.3.5 Key Developments
12.4 Fisher Wallace Laboratories Inc
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Synchron Inc
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 SWOT Analysis
- 12.5.5 Key Developments
12.6 Blackrock Microsystems Inc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 SWOT Analysis
- 12.6.5 Key Developments
12.7 Renishaw Plc
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Abbott Laboratories
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 Neurospine LLC
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 SWOT Analysis
- 12.9.5 Key Developments
12.10 BrainGate
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 SWOT Analysis
- 12.10.5 Key Developments
12.11 NeuroSky Inc
- 12.11.1 Key Facts
- 12.11.2 Business Description
- 12.11.3 Products and Services
- 12.11.4 SWOT Analysis
- 12.11.5 Key Developments
12.12 Neuralink Corp
- 12.12.1 Key Facts
- 12.12.2 Business Description
- 12.12.3 Products and Services
- 12.12.4 SWOT Analysis
- 12.12.5 Key Developments
12.13 NeuroPace Inc
- 12.13.1 Key Facts
- 12.13.2 Business Description
- 12.13.3 Products and Services
- 12.13.4 Financial Overview
- 12.13.5 SWOT Analysis
- 12.13.6 Key Developments
12.14 ONWARD Medical NV
- 12.14.1 Key Facts
- 12.14.2 Business Description
- 12.14.3 Products and Services
- 12.14.4 Financial Overview
- 12.14.5 SWOT Analysis
- 12.14.6 Key Developments
12.15 Paradromics Inc
- 12.15.1 Key Facts
- 12.15.2 Business Description
- 12.15.3 Products and Services
- 12.15.4 SWOT Analysis
- 12.15.5 Key Developments

13. Appendix

13.1 About Us
13.2 Glossary of Terms